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From September 2010 until November 2019, Ireland’s infant vitamin D supplementation policy 14 
recommended administration of 5µg/day of vitamin D3 from birth to 12 months to all infants, regardless 15 
of feeding method. This study aims to examine policy adherence.  16 
Methods 17 
In the prospective COMBINE birth cohort study (recruited 2015-2017), detailed longitudinal 18 
supplement data were examined in 364 infants across the first year of life, according to product type, 19 
dose, frequency and duration. Vitamin D supplement use at 2, 6 and 12 months in COMBINE was 20 
compared with the BASELINE cohort (recruited 2008-2011, n=1949). 21 
Results  22 
In COMBINE, 92% of infants initiated supplementation at birth. The median supplementation duration 23 
was 51 (40, 52) weeks, with a range of 3-52 weeks. While supplementing, most parents (92%) used an 24 
exclusive vitamin D supplement as recommended and 88% gave 5µg/day. Half (51%) gave vitamin D 25 
daily and a further 33% supplemented at least 3-6 times/week. Overall, 30% adhered fully to the policy, 26 
providing 5µg vitamin D3 daily from birth to 12 months. A further 16% were broadly compliant, giving 27 
5µg frequently for the full 12 months. Vitamin D supplement use at 2, 6 and 12 months in COMBINE 28 
was 93%, 89% and 72%, considerably higher than our earlier BASELINE cohort at 49%, 64% and 44% 29 
at the same time points (all P<0.001). 30 
Conclusions 31 
We report a high level of vitamin D supplementation initiation at birth, with full to broad policy 32 
adherence among more than half of infants. There is scope to improve overall compliance by focusing 33 
on supplementation frequency.  34 
Key words: vitamin D, supplementation, policy, adherence, infancy, birth cohort 35 
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Introduction  37 
Pregnancy and early life are periods of particular vulnerability to vitamin D deficiency [1]. Many 38 
authors around the world have reported low vitamin D status (indicated by serum 25-hydroxyvitamin 39 
D [25(OH)D] concentrations) among women during pregnancy [2,3]. A high prevalence of low 25 40 
(OH)D (<25 – 50 nmol/L) has been reported in pregnant women in countries such as Scotland [4], the 41 
Netherlands [5] and Sweden [6], which are at relatively high northerly latitudes. For example, in 42 
Scotland, at 57ºN, 22% of a cohort of pregnant women had a 25(OH)D below 25 nmol/L [4]. Around 43 
the world, particularly among people with darker pigmented skin tones, nutritional rickets has re-44 
emerged as a public health problem [7]. 45 
Ireland is a useful exemplar of a country at high latitude (53oN) with no national antenatal vitamin D 46 
supplementation policy. In a large prospective cohort of women in Cork (51ºN) using gold-standard 47 
25(OH)D analysis, we reported that 44% of women had a circulating 25(OH)D concentration < 50 48 
nmol/L, 17% had a 25(OH)D < 30 nmol/L and 11% were below 25 nmol/L [8]. Given that fetal vitamin 49 
D status is determined by maternal circulating 25(OH)D, this is of great concern [1]. The Cork data 50 
showed that 46% of infants born to the mothers in the prospective cohort had umbilical cord 25(OH)D 51 
< 30 nmol/L and 35% had 25(OH)D < 25 nmol/L [9], similar to estimates from Saraf et al. [3]. 52 
Because 25(OH)D has a short half-life [10] and sun exposure is not recommended for infants [11], 53 
vitamin D intake is crucial in early life for maintenance of adequate vitamin D status [12]. The IOM 54 
and EFSA have both set an adequate intake of 10 µg/day in the first year of life [10,13], while the 55 
Scientific Advisory Committee on Nutrition in the UK set a safe intake of 8.5-10 µg/day [14]. Exclusive 56 
breastfeeding is recommended for the first 6 months of life, with continuation thereafter [15]. However, 57 
breastmilk has been reported to be a poor source of vitamin D [16,17].  58 
Many countries have implemented infant vitamin D supplementation policies. Such policies are safe 59 
and can be effective in improving vitamin D status and reducing incidence of nutritional rickets [18]. 60 
However, their effectiveness is dependent on adherence, which can be poor for reasons such as 61 
inaccessibility and lack of awareness among healthcare professionals and/or parents [19], and 62 
substantial differences in supplementation rates have been reported across Europe [20]. In 2007, in 63 
response to several cases of nutritional rickets in Dublin, mainly among the increasing immigrant 64 
population, the Food Safety Authority of Ireland published an infant vitamin D supplementation policy, 65 
recommending that ‘all infants, from birth to 12 months, whether breastfed or formula fed, be given a 66 
daily supplement of 5 µg (200 IU) vitamin D. This should be provided by a supplement containing 67 
vitamin D exclusively’ [21]. The policy, including a clear implementation plan, was implemented by 68 
the Health Services Executive in 2010, following stakeholder involvement from health promotion, 69 
medical, midwifery, dietetic and pharmacy experts and remained unchanged until November 2019 [22]. 70 
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Following implementation of the vitamin D supplementation policy, specifically designed supplement 71 
products became widely available in pharmacies and supermarkets for purchase without prescription. 72 
Continuous monitoring of policy uptake [20], as well as detailed investigation of supplementation 73 
practices are necessary to ensure maximum public health benefit without risk of excessive vitamin D 74 
intakes. To date, adherence to this policy has not been monitored.  75 
Here, using data from the prospective COMBINE birth cohort study, we report adherence with the 76 
infant vitamin D policy recommendations. Our secondary aim was to examine trends in the use of 77 
supplemental vitamin D in infants over time, using our mature BASELINE birth cohort study.  78 
Methods 79 
Study Design  80 
The COMBINE (Cork Nutrition and Development Maternal-Infant) study, based in Cork, Ireland, is a 81 
longitudinal, prospective birth cohort study. Participants of the Improved Pregnancy Outcomes via 82 
Early Detection (IMPROvED) study (http://www.clinicaltrials.gov; trial ID: NCT01891240) formed 83 
the recruitment pool for the COMBINE cohort [23]. Recruitment for COMBINE commenced in late 84 
2015 and finished in late 2017; 456 IMPROvED participants were recruited to postnatal follow-up in 85 
COMBINE, which included 7 research midwife-led study visits in the first 12 months of life, at hospital 86 
discharge/day 2, 1 month, 2, 4, 6, 9 and 12 months.  87 
Data collection  88 
Specific information on infant nutritional supplementation practices were collected longitudinally using 89 
interviewer-led questionnaires at each study visit, and included supplement type, brand name, frequency 90 
of use and dose. Where applicable, the age supplementation started and/or stopped was collected to the 91 
nearest week, and any changes in supplementation practices were carefully recorded. Participants were 92 
excluded from this analysis if they had dropped-out of the study before 12 months, as their vitamin D 93 
supplementation data could not be verified past the point of drop-out, or had missed a study visit with 94 
subsequent unverifiable supplementation data; complete 12-month data were available for 364 95 
COMBINE participants. 96 
Supplementation policy adherence  97 
Implemented in 2010, the Irish vitamin D supplementation policy stipulated that all infants should be 98 
supplemented with 1) an exclusive vitamin D3 supplement, 2) containing 5 µg vitamin D, 3) daily, 4) 99 
from birth to 12 months [22]. Initiation of supplementation at birth was defined as beginning 100 
supplementation on week 0 or 1. Full policy adherence was defined as adherence to the product type, 101 
supplement dose and frequency recommendations from birth to 12 months. In addition to overall 102 
adherence to 12 months, longitudinal adherence to 2 months (≥ 8 weeks), 4 months (≥ 17 weeks), 6 103 
5 
 
months (≥ 26 weeks) and 9 months (≥ 39 weeks) was also examined to capture trends in policy 104 
adherence. For this purpose, full adherence was defined as longitudinal adherence to product type, dose 105 
and frequency aspects from birth to each time point. Adherence to type and dose recommendations, 106 
where 5 µg vitamin D was given at least often (3-6 times/week) but not always daily, was classed as 107 
substantial adherence and indicates broad compliance. Partial adherence refers to giving vitamin D from 108 
birth to the time-point of interest, although at least one other factor (type, dose and/or frequency) was 109 
not met and not providing vitamin D supplementation for the complete duration of interest (from birth 110 
to the particular time-point) was defined as non-adherence. 111 
Time trends in supplement use 112 
The BASELINE (Babies after SCOPE Evaluating the Longitudinal Impact on Neurological and 113 
Nutritional Endpoints) birth cohort study recruited participants in Cork, Ireland, in the same setting as 114 
the COMBINE cohort, between 2008 and 2011 [24]. In the BASELINE cohort, use of vitamin D-115 
containing supplements was collected in 1949 participants, with data available for 1902 participants at 116 
2 months, 1817 participants at 6 months and 1704 participants at 12 months. The national vitamin D 117 
supplementation policy was implemented in May 2010 while the BASELINE study was ongoing; 118 
70.5% attended their 2 month visit after policy implementation, 79.7% did so at 6 months and 89.9% 119 
of participants attended their 12 month visit after implementation of the vitamin D supplementation 120 
policy.  121 
Statistical Analysis 122 
Statistical analysis was performed using IBM SPSS® version 24.0 (IBM Corp., Armonk, NY, USA) 123 
software for Windows™. Normality testing indicated that descriptive data were non-parametric and 124 
data are presented as median (IQR), with categorical data presented as percentage (%). Chi-square or 125 
Fisher’s Exact tests were used, as appropriate, in comparisons of categorical variables between 126 
participant groups. Differences in continuous variables were assessed using the Mann-Whitney U test.  127 
Results  128 
Maternal and infant characteristics 129 
 130 
Characteristics of COMBINE participants included in this analysis (n = 364) are presented in Table 1. 131 
Median (IQR) maternal age at delivery was 33 (30, 34) years. There was a high proportion of white 132 
(97%) and Irish-born (81%) mothers and 77% had a third level qualification (ordinary bachelor degree 133 
or greater). Forty-eight percent were breastfeeding solely at hospital discharge and the respective 134 
percentages at 6 and 12 months were 24%, and 16%. Participants included in the analysis were slightly 135 
older [33 (30, 35) vs. 30 (25, 33) years], more likely to be in a stable relationship (96 vs. 89% 136 
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partner/married) and to have breastfed at hospital discharge (48 vs. 28%) than those not included (all P 137 
< 0.05), but other maternal and infant characteristics did not differ.  138 
Adherence to the vitamin D supplementation policy in the COMBINE cohort  139 
Product type 140 
Supplements used in the cohort were largely in dropper format, although pump, spray and twist-off 141 
capsule products were also used. All supplements, with the exception of one multi-vitamin product, 142 
used during the COMBINE study contained vitamin D3 (cholecalciferol). Most parents (94.2%) 143 
provided an exclusive vitamin D supplement. In those who used a multi-vitamin, the median (IQR) age 144 
at which this was first provided was 36 (21, 46) weeks. Participants who supplemented with vitamin D 145 
in a multi-vitamin preparation were less likely to have always provided a 5 µg dose of vitamin D (5.0% 146 
vs. 92.9%, P < 0.001). These multi-vitamin products typically contained > 5 µg (68.0%), although 147 
24.0% contained less than 5 µg. 148 
Dose 149 
As per the recommendation, 87.9% used a product containing 5 µg for the duration of supplementation. 150 
Few (1.7%, 6 participants) ever gave < 5 µg, while supplements containing > 5 µg vitamin D were used 151 
by 9.8%. Mothers who supplemented with > 5 µg were less likely to have been born in Ireland (63% 152 
vs. 83%, P = 0.003) and were more likely to be breastfeeding at 6 months (39% vs. 23%, P = 0.034), 153 
suggesting a lower vitamin D intake from formula products.  154 
Supplement doses in products containing more than 5 µg ranged from 7.5 – 25 µg, with 88.9% 155 
containing 10 µg or less. These higher dose supplements were commonly English or Eastern European 156 
brand products, likely designed to meet supplementation recommendations in the country of origin. 157 
Two participants in this study reported exceeding the recommended 5 µg dose with use of products 158 
designed in line with the Irish policy. One participant, who had previously used a non-Irish supplement 159 
containing 10 µg, reported giving a 10 µg dose and another reported providing 2-3 times the 160 
recommended 5 µg/day dose for the first 2 months of life by mistake; attendance at their General 161 
Practitioner confirmed no adverse effects of this. 162 
Frequency 163 
While using supplements, 50.6% of COMBINE participants always gave vitamin D daily and a further 164 
33.3% reported supplementing not less than often. Only 3.3% consistently provided vitamin D less than 165 




The rate of initiation of vitamin D supplementation at birth was 92.3% and a further 3.3% had started 168 
supplementation by week 2. Participants supplemented for a median duration of 51.0 (40.3, 52.0) weeks, 169 
although there was a wide range (3.0 – 52.0 weeks).  170 
Overall adherence 171 
Table 2 details adherence with the vitamin D supplementation policy in COMBINE. From birth to 2 172 
months, 64.3% gave 5 µg vitamin D daily, and the rate of full adherence decreased thereafter to 57.9% 173 
to 4 months, 52.2% to 6 months and 42.7% to 9 months. The rate of substantial adherence from birth to 174 
these follow-up visits was 17.9–22.5%. Approximately one-third (30.3%) of participants adhered fully 175 
to the policy, providing an exclusive 5 µg vitamin D supplement daily from birth to 12 months. A 176 
further 16.1% gave 5 µg vitamin D not less than often for the full 12 month duration, adhering 177 
substantially with the policy. 178 
By 12 months, 15.6% of participants, who provided vitamin D for the full 12 month duration but had 179 
used a multi-vitamin preparation, provided a dose other than 5 µg and/or given a supplement < 3 180 
times/week, were classed as partially adhering. Within these participants, 44.4% had given vitamin D 181 
less than 3 times/week, 22.2% had not always adhered to the dosage recommendation and 31.5% had 182 
not complied with two or more recommendations (type, dose and/or frequency). The rate of longitudinal 183 
non-adherence for the complete duration of birth to 2 months was 7.2%; most of these participants 184 
(88.0%) initiated supplementation after week 1. One-quarter (25.6%) of parents did not supplement for 185 
the complete duration of birth to 9 months, and the median duration of supplementation in these 186 
participants was 26.5 (19.3, 33.0) weeks. The rate of longitudinal non-adherence for the complete 187 
duration of birth to 12 months was 38.0%; the median supplementation duration in these participants 188 
was 33.0 (24.0, 45.0) weeks. 189 
Maternal and infant characteristics and adherence  190 
There were no differences in maternal demographics, including age, white ethnicity, Irish nationality, 191 
education or marital status between those who adhered to the policy and those who did not (all P > 0.05) 192 
(Table 3). Policy adherence did not differ depending on infant sex, gestational age or birthweight (all 193 
P > 0.05). Similarly, the proportion who breastfed was comparable between the two groups (P > 0.05). 194 
Changes over time: comparison of COMBINE and BASELINE at 2, 6 and 12 months 195 
As shown in Table 1, mothers in COMBINE (recruited 2015-2017) were slightly older (all P < 0.001) 196 
than mothers in BASELINE (recruited 2008-2011), but participants in the two cohorts did not differ in 197 
ethnicity, nationality, relationship status or education level (all P > 0.05). The breastfeeding rate was 198 
significantly higher (all P < 0.05) in the COMBINE cohort compared to the BASELINE cohort at 199 
hospital discharge (47.9 vs 40.9%), 2 months (36.1 vs 27.1%), 6 months (24.4 vs 12.3%) and 12 months 200 
(15.5 vs 4.7%). 201 
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While 69.4% of parents in the BASELINE cohort gave their infant a vitamin D-containing supplement 202 
at some stage during the first year of life, 99.2% did so in COMBINE (P < 0.001). As the BASELINE 203 
study spanned the policy implementation, it is interesting to note the difference between participant use 204 
of a vitamin D-containing supplements pre and post policy implementation (3.9 vs 48.7% at 2 months, 205 
15.2 vs. 64.4% at 6 months and 10.9 vs 43.6% at 12 months, all P < 0.001), as shown in Figure 1. 206 
Compared with BASELINE participants assessed after implementation of the supplementation policy, 207 
a higher proportion in COMBINE supplemented with vitamin D at 2 months (93.1 vs. 48.7%), 6 months 208 
(88.7 vs. 64.4%) and 12 months (71.6 vs. 43.6%), all P < 0.001. 209 
Discussion 210 
This is the first detailed analysis of adherence with the national infant vitamin D supplementation policy 211 
in Ireland. These data from the recent COMBINE cohort showed that almost all participants 212 
supplemented with vitamin D at some point during the first year of life and there was a high initiation 213 
rate of supplementation at birth, indicating widespread awareness of the policy. Adherence with dosing 214 
recommendations was also high, suggesting a low risk of excess intakes. Both frequency and duration 215 
of vitamin D supplementation had the greatest effects on overall longitudinal adherence to the policy. 216 
In comparison to our mature BASELINE cohort, we found substantial increases in supplement use since 217 
the policy introduction, suggesting that the infant vitamin D supplementation policy has become well 218 
established since its introduction in 2010.  219 
In 2017, Uday and colleagues published an exploration of adherence to vitamin D supplementation 220 
programmes in Europe [20]. Of the 29 included countries, only 3 (Denmark, Turkey and Israel) 221 
monitored policy adherence nationally. While an adherence rate of ≥ 80% was indicated by 59% of 222 
countries, 31% reported moderate adherence (50-79%) and 10% low adherence (< 50%). An adherence 223 
rate of 59%, estimated from a regional study, was reported for Ireland, although the source of these data 224 
was not provided. Cross-sectional analyses of cohort studies highlight wide variation in 225 
supplementation policy adherence, ranging from < 10% in America at multiple time-points during the 226 
first year of life [25] to 80% in Canada at 2 months of age [26] and 97% in Denmark at 9 months [27]. 227 
Secondary analysis of an infant feeding trial estimated daily (defined as 4-7 times/week) vitamin D 228 
supplementation in ~1% of infants in Australia, ≥ 60% in Southern Europe and ≥ 80% in Northern and 229 
Central Europe [28]. Given that 93% of infants in COMBINE received supplemental vitamin D at 2 230 
months, 89% at 6 months and 72% at 12 months, our data indicates high rates of supplementation. 231 
However, prospective longitudinal data can provide a more in-depth examination of supplementation 232 
practices. Accounting for dose, type, frequency and duration of supplementation, reflecting a strict 233 




In recommending universal supplementation with a low dose 5 µg/day supplement, compared to the 236 
more commonly recommended 10 µg/day, the Food Safety Authority of Ireland determined that this 237 
would prevent serum 25(OH)D concentrations < 25 nmol/L in breastfed infants, whilst ensuring that 238 
intakes in formula fed infants (the majority of infants in Ireland), would not exceed the tolerable upper 239 
intake level (UL) [21]. Adherence to the dose recommendation was high in COMBINE, with almost 240 
90% always providing 5 µg/day while supplementing. Non-adherence to this recommendation generally 241 
reflected use of products not designed to meet the Irish vitamin D supplementation policy, typically 242 
where parents born outside of Ireland were using supplements available in their native countries or 243 
where multi-vitamin products were used. Vitamin D excess in infants has generally been associated 244 
with very large single bolus doses and toxicity is rare [29]. In 2018, EFSA increased the UL to 35 245 
µg/day for infants aged 6-12 months [30], reinforcing the safety of low dose supplemental vitamin D 246 
for infants. Given the high adherence to the 5 µg dose recommendation, risk of vitamin D over-exposure 247 
resulting from a low dose universal vitamin D supplementation policy appears low.  248 
Maternal awareness and knowledge influences uptake of infant vitamin D supplementation [19] and our 249 
data indicates that the policy has become well established, with a high level of policy awareness. This 250 
may be attributed to a clear implementation plan and strong communication by clinical and midwifery 251 
staff. During pregnancy and again after birth, midwifery staff explain the vitamin D supplementation 252 
policy to families and they are provided with an information leaflet, with information also available 253 
online on the health services website. To increase policy reach to at risk minority groups, the 254 
information leaflet has been translated to 9 languages, including French, Arabic, Polish and Chinese. In 255 
addition to promoting its initiation, healthcare professionals play an important role in encouraging 256 
continuation of vitamin D supplementation [31]. In COMBINE, the largest increases in non-adherence 257 
occurred towards the end of the first year of life. The first year of life is unique in the provision of 258 
scheduled public health check-ups and immunisation visits. Harnessing this established network for 259 
ongoing dissemination could provide a sustainable platform for ensuring continued awareness to the 260 
vitamin D supplementation policy, particularly from 6 months onwards. Because monitoring at child 261 
health visits has been associated with increased policy adherence [20], national monitoring may be an 262 
effective strategy to increase and maintain policy adherence, as well as providing useful data, and should 263 
be considered in Ireland and elsewhere. As in other studies [32], our breastfeeding rates did not differ 264 
between those who adhered fully to the policy and those who did not. This likely reflects the universality 265 
of the supplementation policy, which is an advantage in providing clarity and improving overall uptake.  266 
Understanding which specific aspects of a particular policy represent the main barriers to adherence 267 
allows creation of informed supports. In a cross-sectional Canadian analysis, consideration of dose and 268 
frequency substantially lowered vitamin D supplementation policy adherence rates [33]. Here, 269 
frequency of supplementation represented the main driver of incomplete adherence; one-fifth of 270 
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participants never gave vitamin D daily. Frequency of supplementation can affect serum 25(OH)D 271 
concentration achieved [34], thus directly influencing policy effectiveness. Highlighting the importance 272 
of daily supplementation to the sub-group who substantially adhered to the policy but gave vitamin D 273 
frequently, rather than daily, should prove effective in increasing full adherence rates and 274 
encouragement to establish a habitual supplementation routine may be especially beneficial [25,35].  275 
While some studies have reported a variety of maternal demographics, including education, age and 276 
ethnicity to relate to infant vitamin D supplementation practices [28,33], we and others [26] did not find 277 
that adherence differed depending on maternal characteristics. Policy adherence also did not differ 278 
depending on feeding method. A universal supplementation policy, independent of feeding mode, has 279 
been associated with good policy adherence [20] and may be especially beneficial in countries like 280 
Ireland, where changes in feeding patterns across the first year of life are common [36]. However,  since 281 
November 2019, in response to new EU Directives increasing the minimum allowable vitamin D 282 
content of infant formula from 1 to 2 µg/100 kcal [37,38], Ireland now recommends daily 283 
supplementation with 5 µg vitamin D only for breastfed infants and those consuming < 300 mL of 284 
formula [39]. Careful monitoring of the effects of this change on both policy adherence and infant 285 
vitamin D intakes is required, to ensure the risk of vitamin D deficiency and nutritional rickets continues 286 
to be effectively minimised. Data from the UK, which recommends 8.5-10 µg/day vitamin D for 287 
breastfed infants or those consuming < 500ml/day of infant formula [14,40], indicates very low 288 
supplementation rates [20], which may be partly attributable to the complexity of the recommendation. 289 
Given this, both the role of healthcare staff in policy promotion and parental awareness, which have 290 
previously been identified as essential in Irish studies [32,41], will be of increasing importance.  291 
The strengths of this analysis include detailed longitudinal data collection in COMBINE, which 292 
facilitated detailed examination of vitamin D supplementation practices and policy adherence in the 293 
cohort. Examination of supplementation according to product type, dose, frequency and duration 294 
allowed identification of policy strengths and target areas for further improvement. In addition, the 295 
prospective nature of both cohorts, which had a similar demographic profile and were conducted in the 296 
same setting, allowed examination of time trends in vitamin D supplementation over a 5-10 year period. 297 
Well-educated women were highly-represented in COMBINE and the demographic profile of mothers 298 
excluded from analysis differed slightly from those included, which may limit generalisability of 299 
findings. However, neither tertiary education levels, nor other characteristics, differed with overall 300 
adherence in this analysis. Although frequent closely-spaced study visits and interviewer-led 301 
questionnaires minimised the potential for recall bias and misreporting, by nature, this study required 302 
self-report, which may introduce some uncertainty to the results. Because circulating 25(OH)D 303 
concentrations were not measured in infants in COMBINE, the effect of supplementation on vitamin D 304 
status could not be examined. Data on changes in the incidence of nutritional rickets and hypocalcaemic 305 
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seizures in Ireland over this period is of interest. As recent data from the British Paediatric Surveillance 306 
Unit refer to this period of time (42), future adherence studies will have a benchmark.  307 
To conclude, in this well-educated cohort we report a high level of initiation of vitamin D 308 
supplementation at birth, with full to broad policy adherence among more than half of infants. 309 
Adherence with supplement dose and type was high during the first year of life, but there is scope to 310 
improve overall compliance by focusing on frequency of dosing. Given the current lack of an antenatal 311 
vitamin D supplementation policy for pregnant women in Ireland and the widely reported high 312 
prevalence of maternal and infant vitamin D deficiency, a simple, universal infant vitamin D 313 
supplementation policy should be retained to promote continued uptake. 314 
  315 
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Table 1. Participant characteristics in the COMBINE (recruited 2015-2017) and BASELINE 316 
(recruited 2008-2011) birth cohort studies 317 
  318 
Characteristic 
COMBINE 
 (n = 364) 
BASELINE 
(n = 1949) 
P-value 
Maternal    
Age at delivery (years) 33.0 (30.0, 34.3) 31.0 (29.0, 34.0) < 0.001 
< 25 years at delivery  4.4 8.5 0.012 
> 35 years at delivery  15.2 14.9 0.941 
White ethnicity 96.7 98.2 0.097 
Born in Ireland 80.8 82.9 0.373 
Partner (married/defacto relationship) 96.2 94.0 0.131 
Education (≥ 13 years primary and 
secondary education) 
89.0 87.6 0.512 
BMI at 15 weeks’ gestation (kg/m2)a 25.1 (22.9, 27.9) 24.0 (22.1,  26.9)1 < 0.001 
Infant    
Sex - female 43.4 48.9 0.059 
Gestational age (weeks) 40.3 (39.3, 41.0) 40.3 ( 39.1,  41.0) 0.091 
Birthweight (kg)  3.5 (3.2, 3.8) 3.5 ( 3.2,  3.8) 0.598 
Breastfedb 
Hospital discharge 


















Data are presented as median (IQR) or percentage (%) as appropriate 
an = 1185 
bBreastfed solely  
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Table 2. Longitudinal adherence (from birth to each time-point) with the Irish vitamin D 319 
supplementation policy in the COMBINE birth cohort study.  320 
 2 months 4 months 6 months 9 months 12 months 
Full adherencea 64.3 57.9 52.2 42.7 30.3 
Substantial adherenceb 20.2 22.5 20.7 17.9 16.1 
Partial adherencec 8.4 9.8 12.4 13.8 15.6 
Non-adherenced 7.2 9.8 14.7 25.6 38.0 
aAdherence to type, dose and frequency 
bAdherence with type and dose where vitamin D was given at least often (3-6 times/week) but not 
always daily 
cVitamin D given but at least one other factor (type, dose or frequency) was not met 
dDid not give vitamin D for the complete duration of interest (from birth to each time-point) 
 321 
  322 
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Table 3. COMBINE cohort characteristics stratified by adherence to the vitamin D supplementation 323 
policy 324 
  325 
Characteristic 
Overall adherencea 
P-value Yes  
(n = 105) 
No  
(n = 245) 
Age at delivery (years) 33.0 (31.0, 35.0) 33.0 (30.0, 34.0) 0.415 
< 25 years at delivery  3.8 4.9 0.785 
> 35 years at delivery  19.2 13.9 0.212 
White ethnicity 96.2 97.1 0.640 
Born in Ireland 82.9 80.8 0.653 
Partner (married/defacto relationship) 94.3 96.7 0.371 
Education (third level qualification)b 78.8 75.6 0.516 
Family income (euro) 
  < 42,000 
  43-84,000 










Smoked at 2 months post-partum 6.8 7.7 0.780 
Infant sex - female 47.1 41.4 0.324 
Gestational age (weeks) 40.3 (39.4, 40.7) 40.3 (39.3, 41.0) 0.284 





















Data are presented as median (IQR) or percentage (%) as appropriate 
aFull adherence to dose, frequency and type aspects from birth to 12 months 
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Fig. 1 Use of vitamin D-containing supplements at 2, 6 and 12 months in the BASELINE (recruited 349 
2008-2011) and COMBINE (recruited 2015-2017) birth cohort studies. The vitamin D supplementation 350 
policy was implemented in May 2010 while the BASELINE cohort was ongoing. *P < 0.001 351 
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